German Court Upholds Cancellation of CeramTec's Pink Trademark, Bolstering CoorsTek's Competitive Position

A German federal patent court ruling upholding the cancellation of CeramTec's pink trademark for ceramic hip components strengthens CoorsTek Bioceramics' ability to compete in the orthopaedic ceramics market and follows similar decisions in France and the United States.

Chicago Metrowire Staff
••Business
German Court Upholds Cancellation of CeramTec's Pink Trademark, Bolstering CoorsTek's Competitive Position

A ruling by the German Federal Patent Court has upheld the cancellation of CeramTec GmbH's trademark over the color pink for ceramic hip components in Germany, delivering another legal victory to CoorsTek Bioceramics in a long-running dispute between the two companies. The court found that CeramTec's trademark application had been filed in bad faith, with the intention of extending an expiring patent monopoly and keeping competitors out of the market.

The decision matters because it removes a significant barrier to competition in the orthopaedic ceramics supply chain. By invalidating CeramTec's claim to exclusive rights over the color pink for ceramic hip components, the ruling bolsters CoorsTek Bioceramics' ability to market its own ceramic hip replacement components, including its Permallon orthopaedic ceramics line. The outcome follows favorable decisions in France and the United States, suggesting a broader trend against trademark claims that companies may use to prolong market exclusivity after patents expire.

The full implications of the GFPC ruling are detailed in the announcement, which can be viewed by those seeking click here.

CeramTec has appealed the decision, so the legal battle is not yet final. However, CoorsTek cites continued court wins and OEM regulatory clearances as building a more competitive orthopaedic ceramics supply chain. For medical device manufacturers and patients, increased competition could lead to greater choice and potentially lower costs in the ceramic hip implant market. CoorsTek Bioceramics, a wholly owned subsidiary of CoorsTek, has sold over six million components for clinical use since 2005, and the ruling may allow the company to expand its presence in Germany and beyond.

The case underscores the importance of intellectual property strategies in the medical device industry, where companies may seek to use trademarks to extend market control after patents expire. The German court's finding of bad faith sends a signal that such tactics will face scrutiny. With appeals ongoing, the final outcome will be closely watched by competitors and regulators alike.

Blockchain Registration

QR Code for Blockchain Registration